The agency’s accusations focus on Bristol Myers’ claims on its website about the drugs’ efficacy and effect on survival, according to a letter dated Aug. 1 and sent to the company from the FDA’s Office of Prescription Drug Promotion.
Krazati is FDA approved for the treatment of locally advanced or metastatic non-small cell lung cancer.
The FDA received multiple complaints about the false or misleading claims through its Bad Ad Program, the agency wrote in the letter. The agency said in its letter that Bristol Meyers has 15 days from receipt to respond to the concerns.
Read the FDA’s letter here.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
